The discovery of immune checkpoint inhibitors, such as antibodies against programmed cell death protein 1 (PD-1) and its ligand PD-L1, has revolutionized cancer treatment by unleashing the immune system’s ability to recognize and destroy tumor cells [56,57]. The gene discussed is PDCD1; the disease is neoplasm.